Article thumbnail

Have the roles of two functional polymorphisms in breast cancer, R72P in P53 and MDM2-309 in MDM2, become clearer?

By Rodney J Scott


Genetic differences between individuals have been predicted to account for disparate outcomes in patients diagnosed with cancer. The search for genetic determinants has been ongoing for a considerable amount of time and it is only now that insights have been gained into which polymorphisms are most likely to be important in determining not only disease likelihood but also outcome. The quest to be able to accurately predict patient outcomes in breast cancer may now be a step closer as increased sample size is leading to more robust statistical analysis and a better understanding of molecular mechanisms of disease are forthcoming

Topics: Editorial
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2005). Aaltonen L-M, Asltonen LA: The MDM2 promoter polymorphism SNP309TG and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck.
  2. (2004). AJ: A nucleotide polypmorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell
  3. (2006). Choon DYH: No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. Cancer Lett
  4. (2009). Combined eff ects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients. Breast Cancer Res
  5. (2007). De Vivo I: The p53 Arg72Pro and MDM2-309 polymorphisms and risk of breast cancer in the nurses’ health study. Cancer Causes Control
  6. (2008). Delattre J-Y: Infl uence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors. Brain Res
  7. (2005). Foekens JA: Gene-expression profi les to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet
  8. (2007). interact in breast cancer susceptibility? A large pooled seires from the breast cancer association consortium. Cancer Res
  9. (2009). MT: TP53 R72P adn MDM2 SNP309 polymorphisms in modifi cation of childhood acute lymphoblastic leukemia susceptibility. Cancer Genet Cytogenet
  10. (2006). Perou CM: Concordance among gene-expression-based predictors for breast cancer.
  11. (2006). polymorphism on age of tumour onset in Li-Fraumeni syndrome.
  12. (2003). The codon 72 polymorphic variants of p53 have markedly diff erent apoptotic potential. Nat Genet
  13. (2007). van’t Veer LJ: The sinlge-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes.